Efforts to combat bacterial infections by targeting virulence factors are gaining traction, fuelled by the potential to circumvent the development of antibacterial resistance and recent landmark approvals of antivirulence drugs. Here, Otto and colleagues examine the antivirulence drugs in development, highlighting the most promising targets and strategies, as well as caveats to using this approach.
- Seth W. Dickey
- Gordon Y. C. Cheung
- Michael Otto
